Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
699 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01043172 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | completed | Phase 2 | 72 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00383760 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01320254 | PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)(PiCCA) | completed | Phase 2 | 93 | Hannover Medical SchoolOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT01195415 | Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2017 | clinicaltrials |
| NCT00609336 | Perioperative Therapy for Resectable Pancreatic Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01016483 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 141 | EMD SeronoINDUSTRY | 2 | Jul 13, 2017 | clinicaltrials |
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01007552 | A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts | completed | Phase 2 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01206049 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations(GOC-B-P) | completed | Phase 2 | 88 | Vejle HospitalOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00361231 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01954745 | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | completed | Phase 2 | 19 | Massachusetts General HospitalOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01718327 | A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma(SUN-CK) | completed | Phase 2 | 53 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01369420 | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 10 | Angiodynamics, Inc.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT01425879 | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2016 | clinicaltrials |
| NCT02468076 | Radiofrequency Ablation for Biliopancreatic Malignancy(IGNITE-1) | completed | Phase 2 | 18 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01267344 | A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC(BTC) | completed | Phase 2 | 122 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02683538 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies | completed | Phase 2 | 196 | Seoul National University HospitalOTHER | 1 | Apr 5, 2016 | clinicaltrials |
| NCT01692704 | Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy | completed | Phase 1 / Phase 2 | 12 | University of ZurichOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01658943 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy(S1115) | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT01454180 | Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets | completed | Phase 2 | 31 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT01073839 | Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma. | completed | Phase 1 / Phase 2 | 33 | University of ZurichOTHER | 1 | Sep 18, 2015 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01389414 | Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma(Vecti-BIL) | completed | Phase 2 | 89 | Prof. Massimo AgliettaOTHER | 1 | May 28, 2015 | clinicaltrials |
| NCT00474812 | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 34 | Oncolytics BiotechINDUSTRY | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00300950 | Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer | completed | Phase 2 | 176 | GlobeImmuneINDUSTRY | 2 | Apr 6, 2015 | clinicaltrials |
| NCT02351219 | FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer(FLAP) | completed | Phase 2 | 50 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Jan 30, 2015 | clinicaltrials |
| NCT01232829 | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT00577889 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00331682 | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00504192 | A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | completed | Phase 2 | 40 | Soonchunhyang University HospitalOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00091026 | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01082809 | Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma | completed | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT01124786 | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | completed | Phase 2 | 367 | Clovis Oncology, Inc.INDUSTRY | 15 | Apr 17, 2014 | clinicaltrials |
| NCT00203892 | Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma | completed | Phase 1 / Phase 2 | 23 | University of ChicagoOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT00085371 | Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00660140 | Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer | completed | Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Aug 13, 2013 | clinicaltrials |
| NCT00096070 | Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00095966 | Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00033462 | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00397787 | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00028834 | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00075647 | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00238212 | S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jan 3, 2018source: clinicaltrials